At first, we found that the expression levels of TGF-β and MICAL2 were higher in high-grade glioma cells and that MICAL2 was associated with higher p-Smad2 upon evaluation, using immunohistochemistry. This evidence concerns the gene TGFB1 and central nervous system cancer.